Table 1.

Demographic data and clinical examination

Demographic data
Sex (male; female)	49; 95
	MRI 0	MRI 1	MRI 3
Age (years; mean ± SD)	35.8 ± 9.9	36.9 ± 9.9	38.8 ± 9.9
Disease duration (years; mean ± SD)	1.3 ± 2.9	2.3 ± 2.9	4.3 ± 2.9
Disease course (CIS; RRMS; SPMS)	80; 64; 0	36; 107; 1	17; 125; 2
Disease modifying drugs	None 144	None 42; Baseline therapy 100 (DMF 1; GA 32; IFN 66) Escalation therapy 3 (FTY 1; Nat 2)	None 35; Baseline therapy 95 (DMF 20; GA 25; IFN 48; TFN 1) Escalation therapy 15 (FTY 11; Nat 3; RTX 1)
Clinical examination
EDSS (N; median; range)	137; 1.0; 0–6.0	139; 1.0; 0–6.5	136; 1.0; 0–6.5

Abbreviations: CIS, clinically isolated syndrome; DMF, dimethyl fumarate; EDSS, Expanded Disability Status Scale; FTY, fingolimod; GA, glatiramer acetate; IFN, beta interferon; Nat, natalizumab; RRMS, relapsing‐remitting multiple sclerosis; RTX, rituximab; SD, standard deviation; SPMS, secondary progressive multiple sclerosis; TFN, teriflunomide